Abstract
We observed no association between neoplastic epithelial immunostaining for either amphiregulin (AR) or heregulin (HRG) and presence of ER, EGFR/ERBB-2 overexpression, nodal status, or disease recurrence in 34 breast carcinomas. However, stromal cell staining for both correlated with outcome; 29% of stromal cell AR+ cases recurred vs. 85% for AR+ cases (p = 0.001), and 41% of stromal cell HRG- cases recurred vs. 82% of HRG+ cases (p = 0.01). We conclude that both HRG and AR have significant biologic roles in breast carcinoma growth or progression via mediation of host-tumor interactions which favor aggressive tumor behavior.
Original language | English (US) |
---|---|
Pages (from-to) | 75-80 |
Number of pages | 6 |
Journal | Breast Cancer Research and Treatment |
Volume | 45 |
Issue number | 1 |
DOIs | |
State | Published - 1997 |
Keywords
- Amphiregulin
- Breast carcinoma
- Epidermal growth factor receptor
- Heregulin
ASJC Scopus subject areas
- Oncology
- Cancer Research